Patients with higher expressions of SAT-TGFB1 were 4.04 (1.15–14–23) times more likely to present NAFLD whereas increasing VAT-P53 expression was associated with a 0.25 likelihood reduction (0.07–0.85) of having the disease. Here, TP53 is linked to metabolic dysfunction-associated steatotic liver disease.